The company said, “Treace is not issuing full-year 2026 guidance at this time, however, the Company anticipates continued positive procedure volume growth as well as the impact of previously disclosed dynamics, including headwinds related to broader economic conditions and softer consumer sentiment, as well as a product mix shift. The Company plans to provide 2026 financial guidance during its fourth quarter 2025 earnings conference call, which is currently scheduled for Thursday, February 26, 2026, at 4:30 p.m. Eastern Time.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical reports completion of first Lapiplasty Lightning technology case
- Treace Medical price target lowered to $3 from $5 at Stifel
- Treace Medical price target lowered to $3 from $4 at Truist
- Treace Medical Completes New Secured Loan Financing Deal
- Treace Medical secures up to $175M in debt financing